Rise of multidrug-resistant non-vaccine serotype 15A Streptococcus pneumoniae in the United Kingdom, 2001 to 2014

Sheppard, Carmen, Fry, Norman K., Mushtaq, Shazad, Woodford, Neil, Reynolds, Rosy, Janes, Regina, Pike, Rachel, Hill, Robert, Kimuli, Maimuna, Staves, Peter, Doumith, Michel, Harrison, Timothy and Livermore, David M. ORCID: https://orcid.org/0000-0002-9856-3703 (2016) Rise of multidrug-resistant non-vaccine serotype 15A Streptococcus pneumoniae in the United Kingdom, 2001 to 2014. Eurosurveillance, 21 (50). ISSN 1560-7917

[thumbnail of Published manuscript]
PDF (Published manuscript) - Published Version
Available under License Creative Commons Attribution.

Download (195kB) | Preview


Conjugate vaccines have reduced the burden of pneumococcal disease in vaccinated children and unvaccinated adults, but emerging non-vaccine serotypes are concerning, particularly if antibiotic resistant. Against this background, we reviewed serotypes and resistance among pneumococci collected via: (i) the British Society for Antimicrobial Chemotherapy (BSAC) bacteraemia and respiratory surveillances from 2001 to 2014; (ii) Public Health England’s (PHE) ‘invasive isolate’ surveillance from 2005 to 2014 and (iii) received as PHE reference submissions from 2005 to 2014. Representatives were sequenced, with sequence types (STs) deduced. Serotype 15A became increasingly prominent in all series, with many representatives showing ‘triple resistance’ to macrolides, tetracyclines and penicillin. In the PHE and BSAC invasive isolates surveillances, serotype 15A was consistently among the 10 most prevalent types from 2011, but never previously; 26-33% of invasive 15A isolates had triple resistance’. BSAC respiratory isolates were only serotyped in the 2013/4 and 2014/5 (October to September years), with 15A proving the most prevalent serotype in both periods, at 9.1 and 10.7% of isolates, respectively, with 38.2 and 47.8% showing triple resistance. Among pneumococci sent to PHE for resistance investigation, the proportion of 15A isolates was 0-4% annually in the years 2005 to 2008 but rose to 29 and 32% in 2013 and 2014, respectively. Almost all multiresistant 15A isolates were sequence type (ST)63 variants, whereas susceptible 15A isolates were clonally diverse. The rise of resistant serotype 15A pneumococci suggests that pneumococcal conjugate vaccines will need ongoing adaptation.

Item Type: Article
Additional Information: This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.
Uncontrolled Keywords: pneumococcal conjugate vaccine,streptococcus pneumoniae,capsular serotypes,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups: Faculty of Medicine and Health Sciences > Research Groups > Public Health and Health Services Research
Faculty of Medicine and Health Sciences > Research Groups > Epidemiology and Public Health
Related URLs:
Depositing User: Pure Connector
Date Deposited: 24 Sep 2016 00:23
Last Modified: 22 Oct 2022 01:26
URI: https://ueaeprints.uea.ac.uk/id/eprint/60019
DOI: 10.2807/1560-7917.ES.2016.21.50.30423

Actions (login required)

View Item View Item